Dipeptide levels in CKD

• Research type

  Research Study

• Full title

  A research study to investigate dipeptide and metabolite levels in blood from chronic kidney disease (CKD) patients

• IRAS ID

  329280

• Contact name

  Stanley Fan

• Contact email

  s.fan@qmul.ac.uk

• Sponsor organisation

  Barts Health NHS Trust

• Duration of Study in the UK

  1 years, 11 months, 31 days

• Research summary

  Research Summary:
  Itch (pruritus) is common and the Standardised Outcomes in Nephrology (SONG) initiatives flagged that Haemodialysis and Peritoneal Dialysis patients rate this problem highly for research and treatment.

  A cream (MC2-25) has been developed (undergoing clinical trials) that is specifically targeting this uraemic itch (CKD-aP). This cream contains dipeptides that neutralize a uraemic toxin called icocyanate which alters (carbamylates) proteins in the skin that is thought to mediate the CKD-aP.

  Dipeptides are found naturally in humans but they are difficult to measure and the level in patients with kidney disease (CKD) is unknown.

  This study is to determine if dipeptides (and their metabolites) are detectable in patients with CKD.

  Summary of Results:
  The mean seum levels (SD) of dipeptide of Haemodialysis patients was 0.013 (0.04) vs 0.018 (0.011) of patients with chronic kidney disease not on dialysis. The difference was not statistically different by student t-test

• REC name

  West Midlands - South Birmingham Research Ethics Committee

• REC reference

  23/WM/0168

• Date of REC Opinion

  28 Jul 2023

• REC opinion

  Favourable Opinion